Novartis sells parts of Sandoz U.S. to India’s Aurobindo for $900 million

Novartis AG said on Thursday it would sell the dermatology and generic U.S. oral solids portfolios of Sandoz U.S. to India’s Aurobindo Pharma Ltd for $900 million, as the Swiss drugmaker looks to focus on higher growth areas.

…read more

Source:: Reuters – Business News

      

Did you enjoy this article? Join our FREE Newsletter!
I agree to have my personal information transfered to MailChimp ( more information )
Join over 100,000 investors and business leaders worldwide. Get the latest actionable business and investing intelligence before the rest of the crowd.
We hate spam. Your email address will not be sold or shared with anyone else.